Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma,
comprises a heterogenous group of morphologically, genetically, and clinically distinct …

Diffuse large B-cell lymphoma (DLBCL) represents the commonest subtype of non-Hodgkin
lymphoma and encompasses a group of diverse disease entities, each harboring unique …

BACKGROUND Chronotherapy is a drug intervention at specific times of the day to optimize
efficacy and minimize adverse effects. Its value in hematologic malignancy remains to be …

Background We aimed to compare the efficacy of chimeric antigen receptor T (CAR-T) cell
therapy with that of autologous stem cell transplantation (auto-HSCT) in relapsed/refractory …

Abstract MYC oncogene rearrangements (MYC-R) negatively affect survival in patients with
Ann Arbor stage III–IV diffuse large B-cell lymphoma (DLBCL), but their impact in limited …

Introduction Cancer constitutes the primary disease spectrum contributing to the Global
Burden of Disease (GBD). Adolescents and young adults (AYA) aged 15–39 have received …

Haemato-radiology represents a relatively newly emerging, vast, and complex area of
diagnostic imaging. Its complexity arises from the multimodality nature of patient …

Background In early stage diffuse large B-cell lymphoma (ESDLBL), tumor bulkiness is an
important determinant of treatment and prognosis. Tumor bulk is usually measured on …

Incorporation of patients' preferences often leads to improved outcomes when included in
the multidisciplinary tumor conference/board (MTC). However, patients' wishes are not …

Introduction Primary lymphomas of the gynecologic tract are a rare pathology that may
present with typical gynecologic symptoms. Unlike other gynecologic malignancies, surgical …